<p>新泽西州沃伦，2026 年 1 月 29 日（环球新闻通讯社）——Tevogen（“Tevogen Bio Holdings Inc.” 或 “公司”）（纳斯达克：TVGN）今天宣布，当前基于时间和个人表现的长期股票激励计划将进行修改，以使奖励与公司设定的里程碑（包括收入）保持一致。更新后的计划将适用于所有符合条件参与公司长期激励计划的员工、高管、董事和顾问。</p>
<p>Tevogen 创始人兼首席执行官 Ryan Saadi 博士评论道：“Tevogen 最初是一家 T 细胞治疗生物科技公司，现已发展为一家多元化的医疗保健公司，包括可扩展的医疗保健人工智能项目。公司的目标是在 2030 年前推出至少四款重磅产品，并通过我们当前的项目、潜在的资产收购和合资企业在 2026 年实现收入增长。”</p>
<p><strong>关于 Tevogen</strong></p>
<p>Tevogen 是一家基于可负担性、效率和科学严谨原则构建的下一代社会整合医疗企业。该公司利用行业领先的人工智能和精准 T 细胞治疗平台，采用以患者为中心和成本控制的运营模式，并与全球技术领袖进行战略合作，以支持在多个治疗领域开发先进的、拯救生命的疗法以及为更广泛的医疗保健系统提供可扩展的解决方案。</p>
<p>Tevogen Bio 是公司的主要项目，已完成一项概念验证临床试验，证明其单 HLA 限制、基因未修饰的异体 T 细胞的潜力。Tevogen Bio 的产品线涵盖病毒学、肿瘤学和神经学，基于公司的专有 ExacTcell™平台构建。</p>
<p>Tevogen.AI 旨在通过加速靶点检测、帮助降低失败率以及通过专有预测技术支持优化临床试验设计来变革药物开发。该平台利用来自领先技术提供商（包括微软和 Databricks）的云和数据服务，以推进其长期目标，即预测任何给定蛋白质-HLA 组合的蛋白质组，从而实现快速且成本高效的治疗发现。</p>
<p>Tevogen 正在探索未来的战略举措，可能包括国内仿制药、生物类似药、医疗设备以及为医疗服务提供者提供创新保险解决方案。这些项目共同反映了 Tevogen 的使命，即通过更快、更高效和更公平的医疗模式推动可持续创新，扩大患者的获取渠道。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含某些前瞻性声明，包括但不限于与 Tevogen 的研究和制造能力的计划、对未来增长的预期、对医疗保健和生物制药行业的预期，以及 Tevogen 对其产品候选者在治疗传染病和癌症方面的开发、潜在益处和患者获取的预期。前瞻性声明有时可以通过 “可能”、“可以”、“将”、“期望”、“预期”、“可能”、“潜在”、“目标”、“机会”、“项目”、“相信”、“未来” 等词语及其反义词来识别。这些声明基于管理层截至本新闻稿日期的期望、假设、估计、预测和信念，并受到多种因素的影响，包括已知和未知的风险、延迟、不确定性以及其他不在公司控制范围内的因素，这些因素可能导致公司的实际结果、表现或成就与这些前瞻性声明所表达或暗示的结果、表现或其他期望存在重大差异。</p>
<p>可能导致实际结果、表现或成就与前瞻性声明所表达或暗示的结果存在差异的因素包括但不限于：Tevogen 所竞争市场的变化，包括其竞争格局、技术演变或监管变化；国内和全球经济状况的变化；Tevogen 可能无法执行其增长战略或在管理其增长和扩展运营方面遇到困难的风险；Tevogen 可能无法开发和维持有效的内部控制的风险；未能实现 Tevogen 的商业化和开发计划以及识别和实现额外机会的风险，这可能受到竞争、Tevogen 经济增长和管理增长的能力以及招聘和留住关键员工等因素的影响；Tevogen 可能未能跟上快速的技术发展，以提供新的和创新的产品和服务，或在不成功的新产品和服务上进行大量投资的风险；Tevogen 将需要筹集额外资金以充分实现其商业计划的风险；与开发、许可或收购新疗法相关的风险；与 Tevogen 业务相关的监管诉讼或程序的风险；在执行、成本和完成临床前研究和临床试验中固有的不确定性；与监管审查、批准和商业开发相关的风险；与知识产权保护相关的风险；Tevogen 有限的运营历史；以及在 Tevogen 的 10-K 表格年度报告和随后向 SEC 提交的文件中讨论或引用的那些因素。</p>
<p>您不应对前瞻性声明过于依赖，这些声明仅在作出时有效。Tevogen 没有义务更新任何前瞻性声明，除非适用法律要求。</p>
<p><strong>联系方式</strong></p>
<p>Tevogen Bio 通讯部</p>
<p>电话：1 877 TEVOGEN，分机 701</p>
<p>Communications@Tevogen.com</p>
<p>与此公告相关的照片可在 https://www.globenewswire.com/NewsRoom/AttachmentNg/234bc63b-1117-4834-bedc-d86dbafb934d 获取</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZME5UWXlOQ00zTkRBd01UUTRJekl5T0RrNU1UYz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZME5UWXlOQ00zTkRBd01UUTRJekl5T0RrNU1UYz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MThlYmUzNWItMzM0NC00MGU5LTk0NTQtNzVmMTFmM2I3MzIyLTEzMDE0NjctMjAyNi0wMS0yOS1lbg==/tiny/Tevogen-Bio-Inc.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MThlYmUzNWItMzM0NC00MGU5LTk0NTQtNzVmMTFmM2I3MzIyLTEzMDE0NjctMjAyNi0wMS0yOS1lbg==/tiny/Tevogen-Bio-Inc.png"/></p>

医药突破 ETF - ALPS

TVGN

生物科技 ETF - VanEck Vectors

标普生物技术 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

IBBQ

2 倍做多纳斯达克生物技术 ETF - ProShares

纽交所高增长板生物技术指数 ETF - First Trust

纳斯达克生物科技指数 ETF - iShares Nasdaq

TVGNW

<p>Tevogen Bio Holdings Inc.（纳斯达克代码：TVGN）宣布对其长期股票激励计划进行修改，以使奖励与公司里程碑（包括收入）保持一致。该更新的计划将适用于所有符合条件的员工，旨在支持公司到 2030 年推出四款重磅产品的目标。Tevogen 正在发展成为一家多元化的医疗保健公司，利用人工智能和精准 T 细胞疗法在多个治疗领域开发先进疗法。该公司还在探索仿制药、生物类似药和创新保险解决方案的战略举措</p>

<p>WARREN, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that the current time- and individual performance-based long-term stock incentive program will be modified to align awards with defined company milestones including revenue. The updated program will be applicable to all employees, officers, directors and consultants who are eligible to participate in the Company’s long term incentives plan.</p>
<div class="lb-trans"><p>新泽西州沃伦，2026 年 1 月 29 日（环球新闻通讯社）——Tevogen（“Tevogen Bio Holdings Inc.” 或 “公司”）（纳斯达克：TVGN）今天宣布，当前基于时间和个人表现的长期股票激励计划将进行修改，以使奖励与公司设定的里程碑（包括收入）保持一致。更新后的计划将适用于所有符合条件参与公司长期激励计划的员工、高管、董事和顾问。</p>
</div><p>Tevogen Founder and CEO, Dr. Ryan Saadi, commented, “Tevogen began as a T cell therapy biotech and has since evolved into a diversified healthcare company, including a scalable healthcare AI initiative. The Company’s goal is to launch at least four blockbuster products by 2030, and to pursue revenue generation in 2026 through our current programs, potential asset acquisitions, and joint ventures.”</p>
<div class="lb-trans"><p>Tevogen 创始人兼首席执行官 Ryan Saadi 博士评论道：“Tevogen 最初是一家 T 细胞治疗生物科技公司，现已发展为一家多元化的医疗保健公司，包括可扩展的医疗保健人工智能项目。公司的目标是在 2030 年前推出至少四款重磅产品，并通过我们当前的项目、潜在的资产收购和合资企业在 2026 年实现收入增长。”</p>
</div><p><strong>About Tevogen</strong></p>
<div class="lb-trans"><p><strong>关于 Tevogen</strong></p>
</div><p>Tevogen is a next-generation, socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages industry-leading artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and strategic engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system.</p>
<div class="lb-trans"><p>Tevogen 是一家基于可负担性、效率和科学严谨原则构建的下一代社会整合医疗企业。该公司利用行业领先的人工智能和精准 T 细胞治疗平台，采用以患者为中心和成本控制的运营模式，并与全球技术领袖进行战略合作，以支持在多个治疗领域开发先进的、拯救生命的疗法以及为更广泛的医疗保健系统提供可扩展的解决方案。</p>
</div><p>Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. The Tevogen Bio pipeline spans virology, oncology, and neurology, with programs built on the company’s proprietary ExacTcell™ platform.</p>
<div class="lb-trans"><p>Tevogen Bio 是公司的主要项目，已完成一项概念验证临床试验，证明其单 HLA 限制、基因未修饰的异体 T 细胞的潜力。Tevogen Bio 的产品线涵盖病毒学、肿瘤学和神经学，基于公司的专有 ExacTcell™平台构建。</p>
</div><p>Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. The platform utilizes cloud and data services from leading technology providers, including Microsoft and Databricks, to advance its long-term ambition to predict the proteome for any given protein–HLA combination, enabling rapid and cost-efficient therapeutic discovery.</p>
<div class="lb-trans"><p>Tevogen.AI 旨在通过加速靶点检测、帮助降低失败率以及通过专有预测技术支持优化临床试验设计来变革药物开发。该平台利用来自领先技术提供商（包括微软和 Databricks）的云和数据服务，以推进其长期目标，即预测任何给定蛋白质-HLA 组合的蛋白质组，从而实现快速且成本高效的治疗发现。</p>
</div><p>Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen’s mission to advance sustainable innovation and broaden patient access through a faster, more efficient, and more equitable healthcare model.</p>
<div class="lb-trans"><p>Tevogen 正在探索未来的战略举措，可能包括国内仿制药、生物类似药、医疗设备以及为医疗服务提供者提供创新保险解决方案。这些项目共同反映了 Tevogen 的使命，即通过更快、更高效和更公平的医疗模式推动可持续创新，扩大患者的获取渠道。</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.</p>
<div class="lb-trans"><p>本新闻稿包含某些前瞻性声明，包括但不限于与 Tevogen 的研究和制造能力的计划、对未来增长的预期、对医疗保健和生物制药行业的预期，以及 Tevogen 对其产品候选者在治疗传染病和癌症方面的开发、潜在益处和患者获取的预期。前瞻性声明有时可以通过 “可能”、“可以”、“将”、“期望”、“预期”、“可能”、“潜在”、“目标”、“机会”、“项目”、“相信”、“未来” 等词语及其反义词来识别。这些声明基于管理层截至本新闻稿日期的期望、假设、估计、预测和信念，并受到多种因素的影响，包括已知和未知的风险、延迟、不确定性以及其他不在公司控制范围内的因素，这些因素可能导致公司的实际结果、表现或成就与这些前瞻性声明所表达或暗示的结果、表现或其他期望存在重大差异。</p>
</div><p>Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; that Tevogen will need to raise additional capital to fully realize its business plans; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC.</p>
<div class="lb-trans"><p>可能导致实际结果、表现或成就与前瞻性声明所表达或暗示的结果存在差异的因素包括但不限于：Tevogen 所竞争市场的变化，包括其竞争格局、技术演变或监管变化；国内和全球经济状况的变化；Tevogen 可能无法执行其增长战略或在管理其增长和扩展运营方面遇到困难的风险；Tevogen 可能无法开发和维持有效的内部控制的风险；未能实现 Tevogen 的商业化和开发计划以及识别和实现额外机会的风险，这可能受到竞争、Tevogen 经济增长和管理增长的能力以及招聘和留住关键员工等因素的影响；Tevogen 可能未能跟上快速的技术发展，以提供新的和创新的产品和服务，或在不成功的新产品和服务上进行大量投资的风险；Tevogen 将需要筹集额外资金以充分实现其商业计划的风险；与开发、许可或收购新疗法相关的风险；与 Tevogen 业务相关的监管诉讼或程序的风险；在执行、成本和完成临床前研究和临床试验中固有的不确定性；与监管审查、批准和商业开发相关的风险；与知识产权保护相关的风险；Tevogen 有限的运营历史；以及在 Tevogen 的 10-K 表格年度报告和随后向 SEC 提交的文件中讨论或引用的那些因素。</p>
</div><p>You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.</p>
<div class="lb-trans"><p>您不应对前瞻性声明过于依赖，这些声明仅在作出时有效。Tevogen 没有义务更新任何前瞻性声明，除非适用法律要求。</p>
</div><p><strong>Contacts</strong></p>
<div class="lb-trans"><p><strong>联系方式</strong></p>
</div><p>Tevogen Bio Communications</p>
<div class="lb-trans"><p>Tevogen Bio 通讯部</p>
</div><p>T: 1 877 TEVOGEN, Ext 701</p>
<div class="lb-trans"><p>电话：1 877 TEVOGEN，分机 701</p>
</div><p>Communications@Tevogen.com</p>
<div class="lb-trans"><p>Communications@Tevogen.com</p>
</div><p>A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/234bc63b-1117-4834-bedc-d86dbafb934d</p>
<div class="lb-trans"><p>与此公告相关的照片可在 https://www.globenewswire.com/NewsRoom/AttachmentNg/234bc63b-1117-4834-bedc-d86dbafb934d 获取</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZME5UWXlOQ00zTkRBd01UUTRJekl5T0RrNU1UYz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTY0NTYyNCM3NDAwMTQ4IzIyODk5MTc="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MThlYmUzNWItMzM0NC00MGU5LTk0NTQtNzVmMTFmM2I3MzIyLTEzMDE0NjctMjAyNi0wMS0yOS1lbg==/tiny/Tevogen-Bio-Inc.png" alt="" original-src="https://ml.globenewswire.com/media/MThlYmUzNWItMzM0NC00MGU5LTk0NTQtNzVmMTFmM2I3MzIyLTEzMDE0NjctMjAyNi0wMS0yOS1lbg==/tiny/Tevogen-Bio-Inc.png"/></p>

Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue | TVGN Stock News

StockTitan

Tevogen Bio

Invesco Nasdaq Biotechnology ETF

TEVOGEN BIO HOLDINGS INC C/WTS 14/02/2029 (TO PUR COM)

Tevogen 将长期股票激励计划与公司里程碑对齐，其中包括收入 | TVGN 股票新闻